SERUM ALDOSTERONE LEVEL DYNAMICS AND CARDIAC REMODELING IN MYOCARDIAL INFARCTION PATIENTS WITH UNDIFFERENTIATED CONNECTIVE TISSUE DYSPLASIA TREATED WITH SELECTIVE ALDOSTERONE RECEPTOR BLOCKER

Aim. To study serum aldosterone level dynamics and cardiac remodeling characteristics in myocardial infarction (MI) patients with undifferentiated connective tissue dysplasia (UCTD) treated with selective aldosterone receptors antagonist eplerenone.

Study population and methods. A total of 110 MI patients with and without UCTD and 32 healthy controls without cardiovascular pathology and without signs of UCTD were enrolled in the study. Clinical examination, phenotyping, echocardiography and serum aldosterone levels evaluation were performed. MI patients were divided into 3 groups: I (n=20) - patients with UCTD who was treated by eplerenone additionally to basic therapy of MI; II (n=60) - patients without UCTD treated by basic therapy of MI; III (n=30) -patients with UCTD treated by basic therapy of MI only.

Results. All MI patients regardless of UCTD presence had increased serum aldosterone in the first day of MI. In 28 days the significant increase of serum aldosterone level in group I in comparison with groups II, III and control group was observed. Analysis of structural and functional characteristics of the heart in MI patients in a 6 month after MI had shown more significant left ventricle enlargement and decrease of cardiac pump function in group III compared to group I.

Conclusion. Presence of UCTD in MI patients does not affect serum aldosterone levels dynamics. Inclusion of eplerenone in the treatment of MI patients with UCTD during 6 months inhibits left ventricular dilatation and attenuates reduction of its ejection fraction.

1. Kokorin V.A., Lusov V.A., Shaydyuk O.Yu. The prognostic importance of neurohumoral activation in patients with myocardial infarction. Scientific Bulletin. Medicine. Pharmacy. 2011; 10(105):37-43. [in Russian]

2. Perutsky D.N., Makeev T.I., Konstantinov S.L. Main concepts of postinfarction myocard remodeling. Scientific bulletin. Medicine. Pharmacy. 2011; 10(105):51-59. [in Russian]

3. Beygui F., Labbe JP., Cayla G. et al. Early mineralocorticoid receptor blockade in primary percutaneous coronary intervention for ST-elevation myocardial infarction is associated with a reduction of life-threatening ventricular arrhythmia. Int J Cardiol. 2013. Vol. 167. P. 73-79.

4. Nguyen Dinh Cat A., Jaisser F. Exstrarenal effects of aldosterone. Current Opinion in Nephrology and Hypertension. 2012. Vol. 21. P. 147-156.

5. Zadionchenko V.S., Yalymov A.A., Shekhyan G.G. et al. Mineral corticoid receptors antagonists: the place in the practice of a cardiologist. Russian medical journal. 2018; 1(11):120-125. [in Russian]

6. Pitt B., Pfeffer M., Assmann S. et al. Spironolactone for heart failure with preserved ejection fraction. N. Engl. J. Med. 2014. Vol. 370. P. 1383-1392.

7. João P.F., Kévin D., Gilles M. et al. Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study. Clinical Research in Cardiology. 2018. Vol. 107. P. 49-59.

8. Kuzmin O. B., Clinical efficacy of renin-angiotensin-aldosterone system inhibitors in patients with heart failure with impaired renal function. Heart failure 2013; 4 (78):228-233. [in Russian]

9. Zemtsovsky E.V. Dysplastic phenotypes. Dysplastic heart. SPb.: Olga; 2007. С. 80. [in Russian]

10. Trisvetova E.L. Magnesium deficiency and cardiovascular diseases: time to act. Rational pharmacotherapy in cardiology. 2014; 10:99-105. [in Russian]

11. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2012. Vol. 33. P. 1787–1847.

12. Tanaka-Esposito C., Varahan S., Jeyaraj D. et al. Eplerenonemediated regression of electrical activation delays and myocardial fibrosis in heart failure. J. Cardiovasc. Electrophysiol. 2014. Vol. 25. P. 537–544.

13. Lavall D., Selzer C., Schuster P. et al. The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation. J. Biol. Chem. 2014. Vol. 289. P. 6656–6668.

14. Mareev V. Y., Ageev F. T., Arutyunov G. P. et al. National Guidelines of Heart Failure Society Specialists, Russian Society of Cardiology and Russian Scientific Society of Internal Medicine on Diagnosis and Treatment of Chronic Heart Failure (fourth revision). Journal of Heart Failure. 2013; 7 (81):379-472. [in Russian].

15. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. European Heart Journal. 2012. Vol. 33. P. 2569-2619.

16. Glesby M.J., Pyeritz R.E. Association of mitral valve prolapse and systemic abnormalities of connective tissue. J. Amer. Med. Assoc. 1989. Vol. 262. P. 523-528.

17. Antonio Lax., Jesus Sanchez-Mas., Maria C. Asensio-Lopez et al. Mineralocorticoid Receptor Antagonists Modulate Galectin-3 and Interleukin-33/ST2 Signaling in Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction. Jacc: HEART Failure. 2015. Vol. 3. P. 51-58.